Overview

Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy Subjects

Status:
Completed
Trial end date:
2018-10-17
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare the pharmacokinetics (PK) and pharmacodynamics (PD) of MSB11455 and Neulasta in healthy adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Fresenius Kabi SwissBioSim GmbH
Merck KGaA